FindTrial
Sign In

A clinical trial to study the effects of Recombinant Human Erythropoietin therapy in management of anemia in patients suffering from Chronic Renal Failure.

A randomized, open label, comparative study to evaluate the efficacy and safety of Recombinant Human Erythropoietin therapy in management of anemia in patients suffering from Chronic Renal Failure.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2009/091/000786
Enrollment
Unknown
Registered
2010-01-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Renal Failure

Interventions

Intervention1: Recombinant Human Erythropoietin.: 100 IU/kg body weight, thrice a week by I.V. / S.C. route. Control Intervention1: Epox: 100 IU/kg body weight, thrice a week by I.V. / S.C. route.

Sponsors

Lupin Limited India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients of in the age group of 20-60 years Patients with ï?? Haemoglobin ï?? Hematocrit

Exclusion criteria

Exclusion criteria: Exclusion Criteria: Patients suffering from superimposed uncontrolled infection or other active infection Patient suffering from malignancy of bone marrow (leukemia)

Design outcomes

Primary

MeasureTime frame
Increase in Hemoglobin level Increase in Hematocrit level Timepoint: Three Month—

Secondary

MeasureTime frame
Safety and tolerable treatmentTimepoint: Three Month—

Countries

India

Contacts

Public ContactDr Alok Chaturvedi
alokchaturvedi@lupinpharma.com022-66402200

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026